Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Simultaneous Implant Placement With Vertical and Horizontal Bone Augmentation

NCT06313229 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-04-15
Last updated
2026-08-25

Condition(s) studied

Alveolar Bone LossDental Implant Failed

Investigational drug(s) / intervention(s)

implant placement 6 months after ridge augmentationimplant placement Simultaneously with ridge augmentation

implant placement 6 months after ridge augmentation: the deficient ridge was grafted first followed by implant placement after 6-monthes

implant placement Simultaneously with ridge augmentation: the deficient ridge was grafted and followed by implant placement simultaneously

Study summary

The purpose of this study was to report the clinical and radiographical outcomes of using autogenous cortical bone plates combined with sticky allogenic bone graft for augmenting maxillary anterior atrophic combined horizontal and vertical ridge defects with simultaneous versus staged implant placement.

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Good general health at the time of surgery * At least 3 months of healing after tooth extraction * Horizontally and vertical compromised alveolar ridges Exclusion Criteria: * Thick cortex in the labial/buccal with less cancellous bone inside; * Obvious undercut on the labial/buccal side * Uncontrolled periodontal conditions or other oral disorders; * history of radiotherapy in the head and neck region

Primary outcome measure(s)

  • Stability Quotient of Implants (SQI) — 36-month.
    The implant stability was recorded using Osstell TM. Following implant insertion, SQI readings were taken immediately, then again after six and twelve months.
  • Horizontal bone dimensions (HBDs) — 36-month.
    The HBD alterations were assessed by measuring horizontal spacing between the external edges of labial and palatal bony plates at a level 2mm apical of the fixture platform.
  • Peri-implant Bone Density (PBD) — 36-month.
    For consistent measurement of the PBD, 1-mm-diameter Region of interest (RI) was selected and traced 1.2 mm distant from the fixture on the cross-sectional slices followed by counting the threshold pixels inside the RI.

Trial sites (1)

FacilityCityRegionStatus
faculty of dentistry, kafrelsheikh University Kafr ash Shaykh Kafrelsheikh
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06313229 on ClinicalTrials.gov ↗ ← All trials in Egypt